11,030 reports of this reaction
2.5% of all ATORVASTATIN CALCIUM reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for ATORVASTATIN CALCIUM, manufactured by Parke-Davis Div of Pfizer Inc. There are 11,030 FDA adverse event reports linking ATORVASTATIN CALCIUM to DYSPNOEA. This represents approximately 2.5% of all 446,126 adverse event reports for this drug.
Patients taking ATORVASTATIN CALCIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ATORVASTATIN CALCIUM, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ATORVASTATIN CALCIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 11,030 FDA reports for ATORVASTATIN CALCIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.5% of all adverse event reports for ATORVASTATIN CALCIUM, making it a notable side effect.
If you experience dyspnoea while taking ATORVASTATIN CALCIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.